ZenNews› Health› AI Virus Design Splits U.S. Biotech Funding Calcu… Health AI Virus Design Splits U.S. Biotech Funding Calculus Synthetic pathogen breakthroughs force investors to weigh profit against biosafety risk By Oliver Walsh Aug 11, 2026 1 min read Updated: Aug 11, 2026 Share Share X Facebook WhatsApp Copy link How do you feel about this? 🔥 0 😲 0 🤔 0 👍 0 😢 0 Health Virus Design Splits Biotech O Oliver Walsh Health & Climate Oliver Walsh analyses medical research, US health policy and climate science. You might also like › Health AI-Guided Brain Surgery Sets New U.S. Surgical Standard 27 Aug 2026 Health mRNA Cancer Vaccine Trial Stirs U.S. Biotech Investment Rush 01 Sep 2026 Economy AI Energy Shock Risk Splits Fed and White House Advisers 31 Aug 2026 Health FDA Weighs Urine Cancer Test That Rivals Invasive Methods 03 Sep 2026 Health Black Market Retatrutide Floods U.S. as FDA Approval Lags Yesterday Health Pig Kidney Milestone Shifts U.S. Transplant Donor Debate Yesterday Also interesting › US Politics Hegseth Doctrine Tests Civil-Military Norms Mid-Conflict Just now Society Mississippi Hanging Death Exposes Gaps in Rural Autopsy Law Just now US Politics Trump Cash Gifts to Aides Blur Line Between Personal and Official Just now Economy Sapporo Shift Reveals Tariff Fault Lines in U.S. Brewing Economy 8 hrs ago More in Health › Health Pig Kidney Record Puts Xenotransplant Policy in Congress 21 hrs ago Health Pig Kidney Milestone Shifts U.S. Transplant Donor Debate Yesterday Health Black Market Retatrutide Floods U.S. as FDA Approval Lags Yesterday Health FDA Weighs Urine Cancer Test That Rivals Invasive Methods 03 Sep 2026 ← Health AI-Designed Viruses Prompt Senate Biosecurity Alarm Health → FDA's New Weight-Loss Pill Reshapes U.S. Obesity Drug Market
